In women with severe clomiphene-resistant PCOS, we proposed thatthe insulin-lowering agent troglitazone (Rezulin®) could have a positive impact on the ovarian microenvironment by supporting normal follicular growth, ovulation, and successful pregnancy.
Objectives: In women with severe clomiphene-resistant PCOS, we proposed that
the insulin-lowering agent troglitazone (Rezulin®) could have a positive impact on the ovarian microenvironment by supporting normal follicular growth, ovulation, and successful pregnancy.
Design: Observational and prospective, in an academic-affiliated subspecialty private practice.
Methods: Clomiphene-resistant women (n=22) were referred by their gynecologists for subspecialty fertility care, with a desire to avoid gonadotropin therapy. All women were evaluated in detail for objective evidence of anovulation, polycystic ovaries, insulin resistance, androgen excess, and dyslipidemias, and written informed consent was obtained prior to prescribing troglitazone.
Results: Of 22 patients, 21 (95%) had documented ovulatory cycles, and 19 continued in active treatment beyond one cycle. Of 16/19 women continuing with troglitazone ± clomiphene, 13/16 (81%) achieved a pregnancy within 6 months; 10/16 (62%) had healthy ongoing gestations (9 singletons, 1 twin); 4/16 (25%) had spontaneous losses, but one subsequently achieved a normal pregnancy. Of the 3/19 patients who ovulated with troglitazone ± clomiphene but didn't conceive, 2 pursued IVF (both singletons) and 1 patient had gonadotropins in conjunction with troglitazone (singleton).
Conclusions: A high percentage of women with clomiphene-resistant PCOS manifest treatable insulin resistance and hyperinsulinemia. For many of these women, the insulin-lowering agent troglitazone is effective in supporting ovulatory function, leading to ongoing pregnancies. Beneficially, the risks and costs associated with gonadotropin use in these women can potentially be avoided.
Reducing multifetal pregnancy through publicly funded IVF programs
April 26th 2024Learn how a mandatory elective single-embryo transfer policy in publicly funded in vitro fertilization programs significantly decreases multifetal pregnancy rates, offering insights into mitigating risks in assisted reproduction.
Read More
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More